Research Associate - Process Development
BrainChild Bio
Summary
BrainChild Bio is seeking an enthusiastic, self-driven Research Associate to join our Process Core team within Process Development. The successful candidate will be part of a team of associate scientists and engineers that design, execute, and analyze experiments supporting process development studies, material generation runs, automation efforts, and process characterization activities. This position requires positive, collaborative abilities, clear organizational skills, and excellent prioritization to help drive timely delivery of high quality experimental data to advance programs and support regulatory filings.
Job description
Responsibilities
- Design and execute experiments to support cell therapy process development including Design of Experiments (DOE) studies to efficiently optimize unit operations
- Support planning activities prior to study execution including batch record authoring and reagent/material preparation
- Support troubleshooting during study execution and evaluation of potential impacts
- Document experiments in a timely and thorough manner using electronic laboratory notebooks
- Perform statistical data analysis using JMP software
- Author study reports detailing experimental work and summarizing results
- Present experimental findings to cross-functional teams following study completion
Qualifications
- BS in Bioengineering, Chemical Engineering, Biology, or other related discipline
- 2+ years of relevant laboratory experience. Prior experience in cell therapy industry preferred.
- Proficiency with mammalian cell culture sterile technique
- Proficiency with lab electronic notebook and report writing
- Flexibility with work schedule (i.e., occasional weekend work)
Requirements
- BS in Bioengineering, Chemical Engineering, Biology, or other related discipline
- 2+ years of relevant laboratory experience
- Prior experience in cell therapy industry preferred
- Proficiency with mammalian cell culture sterile technique
- Proficiency with lab electronic notebook and report writing
- Flexibility with work schedule (i.e., occasional weekend work)
Company overview
BrainChild Bio is a clinical-stage biotechnology company pioneering the development of CAR T-cell therapies specifically designed for tumors in the central nervous system (CNS). Founded in 2023 as a spin-out from Seattle Children's Hospital, the company adopts a "kids-first" approach, prioritizing pediatric brain tumors with plans to expand its technology platform to adult indications including glioblastoma and brain metastases. The company's initial focus is on diffuse intrinsic pontine glioma (DIPG), an incurable type of childhood brain cancer, leveraging over a decade of translational research conducted at Seattle Children's Therapeutics. BrainChild Bio is advancing a next-generation CAR T-cell therapy platform that integrates synthetic technologies including multiplex targeting, enhanced potency controls, and remote switching capabilities to optimize therapeutic application in CNS tumors. The company's leadership team includes industry veterans with extensive experience in immunotherapy development, including CEO Steven Brugger, who previously led Affinivax through its $3.3 billion acquisition by GSK, and Chief Scientific Officer Dr. Michael Jensen, a pioneer in cancer immunotherapy with over 200 patents in cell and gene therapy. BrainChild Bio represents a significant advancement in addressing the unmet medical need for effective treatments for CNS tumors, particularly in pediatric populations.